API | trelagliptin

trelagliptin Report issue

Small molecule Experimental

AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Trelagliptin is a pharmaceutical drug used for the treatment of type 2 diabetes. ^Wikipedia

Chemistry

SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(Cc3cc(F)ccc3C#N)C1=O
InChIKey: IWYJYHUNXVAVAA-OAHLLOKOSA-N
Mol. Mass: 357.39
ALogP: 0.53 Partition coefficient
ChEMBL Molecules:

trelagliptin

trelagliptin succinate

More Chemistry

Pharmacology

Mechanism of Action:
- Dipeptidyl peptidase 4 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (1)

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 15
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue